ArticleUltrasonography (Seoul, Korea)2026
Non-ablative focused ultrasound induces an adaptive immune response to suppress pancreatic cancer: a preclinical study.
Article in Ultrasonography (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeThis study aimed to investigate whether, and by what mechanisms, focused ultrasound-mediated mechanical stimulation (MS) can induce anti-tumor immunity and elicit an abscopal effect in a pancreatic cancer model.
methodsIn study 1, animals bearing unilateral murine pancreatic tumors (Pan02) in the flank were divided into five groups according to the single or combined use of gemcitabine (Gem), thermal ablation, or MS. Study 2 was conducted in mice bearing bilateral flank tumors to evaluate abscopal effects. Tumor growth suppression, tissue damage, expression of tumor growth-inhibitory genes and cytokines, and anti-tumor cytotoxic T lymphocyte responses were analyzed.
resultsIn study 1, the MS+Gem group exhibited significantly higher levels of interleukin-6, KC-GRO, and tumor necrosis factor-α; higher proportions of CD8+ cells and granzyme B (GrB); and lower Foxp3 expression than the other groups. A significantly higher ratio of CD8+ cells among tumor-infiltrating lymphocytes (TIL) was also observed in the MS+Gem group (P<0.005 at week 2). In study 2, significant growth suppression of the untreated contralateral tumor was observed in the MS+Gem group. Immune analysis of the untreated tumor showed significantly higher proportions of CD8+ cells and GrB, along with a lower proportion of Foxp3+ cells, in the MS+Gem group. The MS+Gem group also demonstrated a higher CD8+/TIL ratio in the untreated tumor.
conclusionMS+Gem effectively suppressed tumor growth, promoted apoptosis-related factors, and enhanced intratumoral infiltration of cytotoxic T cells in treated tumors. In addition, MS+Gem induced an abscopal effect in untreated tumors, suggesting its potential to mediate systemic anti-tumor immune responses in pancreatic cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.